Targeting MYC with modular synthetic transcriptional repressors derived from bHLH DNA-binding domains.
Thomas E SpeltzZeyu QiaoColin S SwensonXianghang ShangguanJohn S CoukosChristopher W LeeDeborah M ThomasJesse SantanaSean W FanningGeoffrey L GreeneRaymond E MoelleringPublished in: Nature biotechnology (2022)
Despite unequivocal roles in disease, transcription factors (TFs) remain largely untapped as pharmacologic targets due to the challenges in targeting protein-protein and protein-DNA interactions. Here we report a chemical strategy to generate modular synthetic transcriptional repressors (STRs) derived from the bHLH domain of MAX. Our synthetic approach yields chemically stabilized tertiary domain mimetics that cooperatively bind the MYC/MAX consensus E-box motif with nanomolar affinity, exhibit specificity that is equivalent to or beyond that of full-length TFs and directly compete with MYC/MAX protein for DNA binding. A lead STR directly inhibits MYC binding in cells, downregulates MYC-dependent expression programs at the proteome level and inhibits MYC-dependent cell proliferation. Co-crystallization and structure determination of a STR:E-box DNA complex confirms retention of DNA recognition in a near identical manner as full-length bHLH TFs. We additionally demonstrate structure-blind design of STRs derived from alternative bHLH-TFs, confirming that STRs can be used to develop highly specific mimetics of TFs targeting other gene regulatory elements.
Keyphrases
- transcription factor
- dna binding
- protein protein
- circulating tumor
- cell proliferation
- cell free
- genome wide identification
- small molecule
- binding protein
- cancer therapy
- public health
- induced apoptosis
- poor prognosis
- gene expression
- oxidative stress
- signaling pathway
- amino acid
- pi k akt
- simultaneous determination
- cell death
- circulating tumor cells